Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

BACKGROUND: Dysregulated inflammation is associated with poor outcomes in COVID-19. We aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating factor inhibitor) and infliximab (a tumour necrosis factor inhibitor) in hospitalised patients with COVID-19, to prioritise ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Benjamin A, Veenith, Tonny, Slade, Daniel, Gaskell, Charlotte, Rowland, Matthew, Whitehouse, Tony, Scriven, James, Parekh, Dhruv, Balasubramaniam, Madhu S, Cooke, Graham, Morley, Nick, Gabriel, Zoe, Wise, Matthew P, Porter, Joanna, McShane, Helen, Ho, Ling-Pei, Newsome, Philip N, Rowe, Anna, Sharpe, Rowena, Thickett, David R, Bion, Julian, Gates, Simon, Richards, Duncan, Kearns, Pamela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8676420/
https://www.ncbi.nlm.nih.gov/pubmed/34922649
http://dx.doi.org/10.1016/S2213-2600(21)00460-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8676420/
https://www.ncbi.nlm.nih.gov/pubmed/34922649
http://dx.doi.org/10.1016/S2213-2600(21)00460-4

Ejemplares similares